Cost of Revenue Comparison: Xenon Pharmaceuticals Inc. vs Xencor, Inc.

Cost of Revenue: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, cost management is crucial for sustaining innovation. This chart compares the cost of revenue for Xenon Pharmaceuticals Inc. and Xencor, Inc. over the past decade. From 2014 to 2023, Xencor, Inc. has seen a staggering increase of over 1,270% in its cost of revenue, peaking at approximately $254 million in 2023. In contrast, Xenon Pharmaceuticals Inc. experienced a more moderate rise of around 2,740%, reaching about $168 million in the same year.

Key Insights

• 2014-2017: Xencor's cost of revenue grew steadily, while Xenon maintained a lower, more stable trajectory.
• 2018-2023: Both companies saw significant increases, with Xenon catching up rapidly.

This data highlights the contrasting financial strategies and growth trajectories of these two biotech leaders, offering valuable insights for investors and industry analysts.